CBD (cannabidiol) is a popular product these days that people use for everything from relieving pain and anxiety to promoting sleep and treating depression. With the sudden rise of using CBD people get more concerned about failing a drug test due to detection of CBD oil. Although medical marijuana is legal in 33 states, using […]
CBD (cannabidiol) is a popular product these days that people use for everything from relieving pain and anxiety to promoting sleep and treating depression. With the sudden rise of using CBD people get more concerned about failing a drug test due to detection of CBD oil. Although medical marijuana is legal in 33 states, using it can lead to a positive drug test and make some problems for you. If you are already a CBD user, you are probably aware of the fact that CBD is different from THC which has psychoactive effects. The first thing you should know is that what turns a drug test positive is the level of THC not CBD, so that is a relief if you are a user and you have to take a drug test in a few days. However, there are many products out on the market and not all the CBD products are completely THC free. So, you have to be careful and consider a few facts before buying the right product; also learn more about other reasons that cause you to fail a CBD drug test and find out what can be done to prevent it.
Does CBD Contain THC?
When you take a drug test, the only active component in marijuana which turns up positive is THC. But most people are under the impression that CBD oil is completely THC-free and that is not necessarily true. Although the level of THC in CBD oil is so low that cannot cause a high, it might be detected in a drug test in a few cases. First of all, the source of the cannabis that is used to produce CBD oil, can affect the test results. Cannabis is a term which generally describes hemp and marijuana plants. These two are different varieties of cannabis genus, however we describe them both as cannabis plant. The primary difference between the two is that hemp is almost free of THC. in fact, you can only describe a cannabis strain as hemp if it is proven to have less that 0.3 percent THC. This is the reason that makes hemp legal and able to be used in various products.
Since most of the CBD products are made of hemp, not marijuana, you might ask what is there to worry about. When the products you buy are legally required to contain only 0.3 percent THC, you should be able to pass a drug test. But the problem is that the harvesting and refinement methods can also change this amount. The extraction method determines whether the active CBD compound gets processed as a “full spectrum oil”, “broad spectrum CBD” or CBD isolate. Let’s find out the differences between these three main CBD products:
Full Spectrum CBD extracts contains all of the natural compounds in the plant. So, if you buy a full spectrum product it contains CBD alongside terpenes, flavonoids and other cannabinoids such as THC. Since these products are extracted from marijuana instead of hemp, it might contain varying amounts of THC (not the legally declared 0.3 percent which is the level of THC in all the products extracted from hemp plant). Also, you should be aware of the fact that many of the manufacturers do not declare where their full spectrum extracts come from; therefore, it can be difficult to say how much THC might be present in the product.
Broad Spectrum CBD, just like full spectrum CBD products contain additional compounds found in the plant. However, in these products the only compound that is removed completely is THC. So, if buy broad spectrum products, from a reputable provider, there is nothing to worry about before taking a drug test.
CBD isolate is pure CBD, meaning that it does not contain any additional compound from the plant it was extracted from. CBD isolate typically comes from hemp plants and as mentioned before, hemp-based products should not contain THC.
How Much THC Will Register on a Drug Test?
Drug tests detect for THC or one of its main metabolites, THC-COOH. Based on the data released by Mayo Clinic Proceedings from 2017, federal workplace drug testing was established to avoid showing the trace of THC or THC-COOH below the cut-off value. In other words, passing a drug test does not mean that there is no THC in your body, it just means that it is below a certain level.
Urine test is the most common test for cannabis, especially in the workplace. In urine, THC-COOH must be at least 50 nanograms per milliliter to trigger a positive test. And you should know that generally, it is detectable in urine for almost 3 to 15 days, depending on the dose and frequency of use.
Blood test is not that common for drug screening, since THC quickly eliminates from the bloodstream. Although THC metabolites are detectable for seven days, THC remains in plasma for up to five hours. In all 33 states where cannabis is legal, a THC blood concentration of 1.2 or 5 ng/mL will fail the drug test.
Other Reasons for Failing a CBD Drug Test
Except using CBD oil which contains more than 0.3 percent THC, there are other reasons for failing a drug test.
Cross Contamination of THC
If you buy CBD oil from cannabis dispensaries instead of an online retailer, there is a chance of cross-contamination during manufacturing process. It can also happen at home. If CBD oil is around other substances that contain THC, cross-contamination can occur and lean to a failed drug test.
Secondhand Exposure to THC
Depending on the potency of marijuana and the size and ventilation of the area, you can absorb THC through secondhand smoke. Although it is unlikely to receive a positive drug test in this case, researchers believe it is still possible.
Since CBD products are not consistently regulated by FDA, it is not uncommon for sellers to mislabel their products as THC-free hemp when in reality, it is a low-quality oil extracted from marijuana, meaning that it does contain THC. In fact, one study discovered that almost 70 percent of CBD products are not labeled properly. So, it is heavily recommended to do a thorough research before trusting an online seller and always check the labels of the products you are about to purchase to see if it has any lab-approved label.
CBD Turning into THC in the Body
Some sources have reported rare cases of false positive test results which have come from CBD oil breaking down in acidic conditions and turning into THC. This chemical transformation can occur in the human stomach. However, this is not theoretically proven and there are contradictory research results suggesting that this might be the result of using “less purified CBD productions”.
How to Avoid a Positive CBD Drug Test?
If you use CBD oil on a daily basis and you are about to apply for a job, you should take precautions to avoid a positive drug test. Although you may have heard that you never have to worry about a positive drug test with CBD products, there have been cases showing that this claim is not entirely valid. Due to the inconsistency of manufacturing CBD products, there is a chance that the product you have bought as a hemp-driven oil, is actually a low-quality CBD extracted from marijuana.
Therefore, if your doctor has recommended CBD oil to improve your sleep, or to manage mild depression and anxiety, take these steps into consideration before purchasing a CBD product and going on with a drug test:
Do thorough research to make sure that the CBD product you are about to buy is pure, isolate and extracted from hemp plants that has grown inside U.S.
Remember that a reputable dealer, whether you are shopping online or in-store, is the most important thing even if you are not about to take a drug test. Ask questions about product processing techniques and the possibility of cross-contamination. Look for the lab report on the provider’s website to check the amount of THC presents in CBD oil.
Avoid secondhand exposure to marijuana.
Although it is relatively impossible to get a false positive on a drug test from CBD oil, you would be better to be careful or you might be one of those rare cases that have lost a job over using CBD products. Since CBD products are not very well regulated, there is no guarantee that the product you are buying does not contain more that 0.3 percent THC (the amount that will not be detected on a drug test).
Taking utmost caution when purchasing CBD oil is the best way to ensure its purity which is not just important for passing a drug test.
The Biden Presidency Looks To Be Installing Several Pro-Cannabis People Into Key Roles In Government
After Kamala Harris was nominated to be President Elect Joe Biden’s running mate, we knew that brighter days were ahead for the cannabis industry……..and the market seemed to agree with us. After Joe Biden was projected to win the election, the cannabis sector recorded strong moves to the upside for almost two months. Although the […]
After Kamala Harris was nominated to be President Elect Joe Biden’s running mate, we knew that brighter days were ahead for the cannabis industry……..and the market seemed to agree with us.
After Joe Biden was projected to win the election, the cannabis sector recorded strong moves to the upside for almost two months. Although the sector has come off its recent highs, we believe the recent additions to President Elect Joe Biden’s cabinet send a very bullish sign to the cannabis industry.
During the last month, President Elect Joe Biden has announced several key cannabis-friendly additions to his cabinet. When you combine the democrats winning two key senate seats in Georgia (and became the majority of both the House of Representatives and the Senate) with the recent additions to the cabinet, we believe that the US cannabis industry is going to flourish.
Most recently, President elect Joe Biden selected former South Carolina Democratic Party Chair Jaime Harrison to lead the Democratic National Committee (DNC). He is a strong supporter of cannabis legalization and will be responsible for coordinating Democrats’ national political activities. Harrison still needs to be confirmed by party leaders, but we are confident that he will.
When Harrison ran for a Senate seat in South Carolina, he said that the US should legalize, regulate and tax cannabis like alcohol and tobacco. We are favorable on his appointment and believe that his views on cannabis will be reflected in the Democrats’ national political activities.
While we can hope for the legalization of cannabis the federal level, we believe the new administration (and government) will quickly pass cannabis decriminalization legislation. If we see cannabis decriminalized, we believe that companies will quickly notice significant margin appreciation. If cannabis is decriminalized, 280 E should be revoked, and this would prove to be a substantial catalyst for companies.
280E is the worst legislation we have ever seen in any industry. The rule does not allow companies to deduct basic business expenses and makes it much more challenging for operators to reach profitability. We believe the revoking of 280E is inevitable and is something that our readers should be aware of.
Michael Berger is Managing Partner of StoneBridge Partners LLC. SBP continues to drive market awareness for leading firms in the cannabis industry throughout the U.S. and abroad.
MustGrow Achieves 100% Control of Root-Rot Disease Infecting Key Plant-Based Protein Crops
MustGrow Biologics Corp. (CSE: MGRO) (OTC: MGROF) (FSE: 0C0) is pleased to announce successful laboratory test results of its patented mustard-derived biopesticide on Aphanomyces euteiches zoospores (“Aphanomyces“) via an independent third party facility: 100% control at economic application rates within 24 hours. MustGrow will now advance to larger scale greenhouse and field tests. Study results […]
MustGrow Biologics Corp. (CSE: MGRO) (OTC: MGROF) (FSE: 0C0) is pleased to announce successful laboratory test results of its patented mustard-derived biopesticide on Aphanomyces euteiches zoospores (“Aphanomyces“) via an independent third party facility: 100% control at economic application rates within 24 hours. MustGrow will now advance to larger scale greenhouse and field tests. Study results and applicability are patent-protected under MustGrow’s existing suite of issued patents.
MustGrow’s remarkably safe and effective organic biopesticide is plant-based – harnessing the mustard seed’s natural defense mechanism to control diseases, pests, and weeds with an organic food-grade biopesticide.
Aphanomyces is a water mould pathogen responsible for root-rot disease, infecting a variety of peas, lentils and other legumes collectively referred to as pulse crops. The disease causes severe root damage and wilting, with yield losses ranging from 10% to 100% in infected fields (1). Canada is one of the world’s largest producers (~9.2 million tons; 2019) and exporters of pulse crops (2). Industry experts conservatively estimate $20 million in annual pulse crop losses in Canada and $100 million globally caused by Aphanomyces (1). Current treatment measures cannot control Aphanomyces – they are only able to slow down the spread and reduce the incidence and severity of the disease.
“It is great to see MustGrow’s mustard plant-based biopesticide continue to perform, particularly with 100% disease control measured at exceptionally low application rates. The level of control of hard-to-kill diseases we continue to achieve combined with the beneficial properties of our product for soil health provide a great opportunity for improved yields for farmers and a more robust food supply,” remarked Colin Bletsky, COO of MustGrow. “I am very hopeful that we can potentially provide a valuable crop-protection tool for pulse crop farmers.”
Plant-Based Crop Protection for Plant-Based Protein
MustGrow feels it makes both logical and ecological sense to protect plant-based protein crops with plant-based crop protection inputs. MustGrow’s product is a pre-plant soil treatment, meaning application to the soil occurs before crops are planted. Application of MustGrow’s biopesticide returns organic plant material to the soil through this pre-plant treatment process as a potential alternative to using synthetic chemicals.
According to MarketsandMarkets and analysis by EY-Parthenon, the global plant-based protein market size is projected to grow from US$12 billion in 2019 to US$28 billion by 2025 (CAGR of 15%). This is attributed to several drivers, predominantly rising consumer health-consciousness, growing prevalence of protein-rich pulse crop food products, and technological innovations in plant-based protein extraction. To accommodate the rise of plant-based protein demand, Fior Markets estimates the global pulse crops market will grow from US$16.2 billion in 2017 to US$24.3 billion by 2025 (CAGR of 5.2%).
The interest in MustGrow’s plant-based biopesticide is increasing as farmers, consumers and investors seek ‘natural biological’ alternatives to synthetic chemical pesticides. Adverse global climate and weather events are expected to negatively impact food supply for a growing human population. Warmer temperatures are expected to increase pest infestations and with more pests there will be more damage to crops. The development of safe and effective biopesticides will be critical for future food security and environmentally sustainable agriculture.
MustGrow is a publicly traded (CSE: MGRO) (OTC: MGROF) (FSE: 0C0) agriculture biotech company focused on providing natural science-based biological solutions for high value crops, including fruits & vegetables and other industries. MustGrow has designed and owns a U.S. EPA-approved natural solution that uses the mustard seed’s natural defence mechanism to protect plants from pests and diseases. Over 110 independent tests have been completed, validating MustGrow’s safe and effective signature products. The product, in granule format, is EPA-approved across all key U.S. states and by Health Canada’s PMRA (Pest Management Regulatory Agency) as a biopesticide for high value crops such as in fruit & vegetables. MustGrow has now concentrated a liquid format, TerraMG, and with regulatory approval, could be applied through standard drip or spray equipment, improving functionality and performance features. In addition, this new mustard-derived technology could have other applications in several different industries from pre-plant soil treatment to post harvest pest and disease control.
The Company has approximately 40.7 million basic common shares issued and outstanding and 50.6 million shares fully diluted. For further details please visit www.mustgrow.ca.
Certain statements included in this press release constitute “forward-looking statements” which involve known and unknown risks, uncertainties and other factors that may affect the results, performance or achievements of MustGrow.
Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects”, “is expected”, “budget”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might”, “occur” or “be achieved”.
Forward-looking statements are subject to a number of risks and uncertainties that may cause the actual results of MustGrow to differ materially from those discussed in such forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, MustGrow.
These risks are described in more detail in MustGrow’s Prospectus and other continuous disclosure documents filed by MustGrow with the applicable securities regulatory authorities and available at www.sedar.com. Readers are referred to such documents for more detailed information about MustGrow, which is subject to the qualifications, assumptions and notes set forth therein.
This release does not constitute an offer for sale of, nor a solicitation for offers to buy, any securities in the United States.
Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
Premium Cannabis Brands Are Going All In With Celebrity Endorsements
The cannabis industry is one of the most attractive growth markets and we believe that it is still in the early innings of a major growth cycle. According to an analyst report from Cowen and Company, the overall market for cannabis and cannabinoid derivatives is expected to reach $34 billion by 2025 and we believe […]
The cannabis industry is one of the most attractive growth markets and we believe that it is still in the early innings of a major growth cycle. According to an analyst report from Cowen and Company, the overall market for cannabis and cannabinoid derivatives is expected to reach $34 billion by 2025 and we believe this is a conservative estimate.
Going, forward, the US cannabis industry is positioned to record strong growth under a democratic administration, and we are favorable on the current trend. One of the more interesting trends that we identified is related to the number of celebrities that are launching cannabis brands and are executing on a strategy to capitalize on a burgeoning industry.
From Snoop Dogg to Seth Rogan, several high-profile celebrities were early movers on the cannabis industry, and this is a trend that has become more significant over the last two years. We are favorable on how these celebrities are benefiting from the strength of their respective fan base and will monitor how these brands are able to gain traction.
Today, we want to highlight 3 premium cannabis brands that are backed by a celebrity and provide more insight on how this trend has evolved over the last few years. Although we do not expect every celebrity backed cannabis brand to perform well, we believe these brands are better positioned to be successful over the long-term.
Canopy Growth and Snoop Dogg
In 2016, Canopy Growth Corporation (WEED.TO) (CGC) became one of the first Canadian Licensed Producers (LPs) to launch a cannabis brand that was backed by a celebrity. The agreement was with Snoop Dogg and the brand did not perform as well as expected. Through this venture, we believe that Canopy Growth learned a lot about the challenges that are associated with launching a celebrity backed cannabis brand.
Prior to forming a relationship with Canopy Growth, Snoop Dogg was a well-known cannabis user and activist. Although the agreement with the Canadian LP did not perform well, Snoop Dogg was paid in stock and due to the performance of Canopy Growth, this proved to be a smart decision.
A few years after the agreement was announced, Snoop Dogg launched a cannabis venture capital firm called Casa Verde to make seed and Series A investments in ancillary companies (non-plant touching businesses). One of Casa Verde’s initial investments was LeafLink, a business-to-business marketplace that’s designed to connect cannabis brands with retailers on a single platform. LeafLink is considered to be a high-profile ancillary cannabis company and we are impressed with his ability to identify attractive investment opportunities.
In late 2020, Casa Verde Capital reported to have completed an $100 million financing for its second investment fund (according to documents filed with the SEC). Currently, Casa Verde has not announced any targets for the new venture capital fund, but we expect this to change in the near future.
Martha Stewart Launches a CBD Brand
Martha Stewart is another high-profile celebrity to enter the cannabis industry. Like Snoop Dogg, she entered into an agreement with Canopy Growth that is focused on the cannabidiol (CBD) vertical. The agreement comes several years after the Canadian LP announced the relationship with Snoop Dogg and the relationship with Martha Stewart has already proved to be a value driver for the company.
A few months ago, Canopy Growth announced an important milestone and reported to have released its Martha Stewart CBD Wellness Gummies Sampler. We are favorable on the relationship with Martha Stewart due to the size of her following and will monitor how the brand performs this year.
One of the reasons we consider Martha Stewart to be a strategic partner is related to the demographic of her fan base. We believe that she appeals to the baby boomer generation and expect Canopy Growth to benefit from having leverage to this demographic. So far, the average age of cannabis consumers is younger than Martha Stewart’s fan base and we are favorable on how this further differentiates Canopy Growth from other operators in the sector.
Gage Cannabis and Cookies is an Emerging Growth Story
Gage Cannabis a leading operator in Michigan and has formed an exclusive partnership with one of the best-known cannabis brands, Cookies. The leading cannabis brand was started by California rapper Berner and has a massive following. From the quality of the genetics to the packaging of the finished product, Cookies has been nothing short of an execution story and has a cult-like following.
Last year, Gage opened a Cookies branded flagship cannabis dispensary in the heart of Detroit and we are bullish on this opportunity. The flower that is sold by Cookies is very expensive when compared to other brands and the high price point has not impacted the amount of demand for it.
We believe that Gage Cannabis has the necessary traits to be successful in the cannabis industry and will continue to closely monitor the operation. The company is led by a management team that has a proven track record of success and we are favorable on this aspect of the story. We believe that Gage has attractive growth prospects, a favorable risk-reward profile, and is an opportunity to be aware of.
If you are interested in learning more about celebrities that are forming cannabis brands, please email firstname.lastname@example.org with the subject “Celebrity Backed Cannabis Brands” to be added to our distribution list.
Michael Berger is Managing Partner of StoneBridge Partners LLC. SBP continues to drive market awareness for leading firms in the cannabis industry throughout the U.S. and abroad.